Trevi Therapeutics (TRVI) Stock Forecast, Price & News

Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics or view top-rated stocks.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 397,500 shares, a decline of 27.6% from the April 15th total of 548,900 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 0.3 days. Currently, 11.7% of the company's shares are short sold.
View Trevi Therapeutics' Short Interest.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Trevi Therapeutics.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. During the same period last year, the business posted ($0.43) EPS.
View Trevi Therapeutics' earnings history.

What price target have analysts set for TRVI?

2 Wall Street analysts have issued twelve-month price targets for Trevi Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Trevi Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts' price targets for Trevi Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:

• Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 57, Pay $662.64k)
• Dr. Thomas R. Sciascia, Co-Founder & Chief Medical Officer (Age 69, Pay $476.25k)
• Ms. Lisa Delfini, Chief Financial Officer (Age 52)
• Mr. Christopher Galletta, Controller & Chief Accounting Officer (Age 44)
• Mr. Frank P. Muscolo, Exec. Officer (Age 65)
• Dr. William P. Forbes Pharm. D., Pharm.D., Chief Devel. Officer (Age 60)
• Ms. Danine Summers, VP of Medical Affairs (Age 64)

Who are some of Trevi Therapeutics' key competitors?

Some companies that are related to Trevi Therapeutics include Zymeworks (ZYME), Fulcrum Therapeutics (FULC), PyroGenesis Canada (PYR), Khosla Ventures Acquisition (KVSA), Rigel Pharmaceuticals (RIGL), Mersana Therapeutics (MRSN), Phathom Pharmaceuticals (PHAT), Kezar Life Sciences (KZR), Enochian Biosciences (ENOB), Seres Therapeutics (MCRB), Aerovate Therapeutics (AVTE), Akero Therapeutics (AKRO), InterCure (INCR), Generation Bio (GBIO) and Aadi Bioscience (AADI).
View all of TRVI's competitors.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include MAI Capital Management (3.98%), Vanguard Group Inc. (0.40%), Renaissance Technologies LLC (0.30%), WealthTrust Axiom LLC (0.25%), State Street Corp (0.10%) and BlackRock Inc. (0.09%). Company insiders that own Trevi Therapeutics stock include Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends for Trevi Therapeutics.

Which institutional investors are selling Trevi Therapeutics stock?

TRVI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and BlackRock Inc..
View insider buying and selling activity for Trevi Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Trevi Therapeutics stock?

TRVI stock was acquired by a variety of institutional investors in the last quarter, including MAI Capital Management, WealthTrust Axiom LLC, State Street Corp, Virtu Financial LLC, Commonwealth Equity Services LLC, and Vanguard Group Inc..
View insider buying and selling activity for Trevi Therapeutics or or view top insider-buying stocks.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.25.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $87.05 million. The company earns $-33.94 million in net income (profit) each year or ($1.350010) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 24 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 304-2499 or via email at [email protected].